Statement: both the primary and secondary trials reported multiple cases of conjunctivitis
Primary_evidence: Adverse Events 1:   Total: 16/48 (33.33%)   Febrile neutropenia grade 3 3/48 (6.25%)   Neutropenia grade 3 1/48 (2.08%)   Holocraneal cephalea 1/48 (2.08%)   Hypersensibility reaction grade 3 2/48 (4.17%)   Palmoplantar erythrodysesthesia grade 3, stomatitis grade 3 1/48 (2.08%)   Neutropenia grade 4, fever grade 1, oral mucositis grade 3 1/48 (2.08%)   Catheter - related infection grade 3 1/48 (2.08%)
Secondary_evidence: Adverse Events 1:   Total: 21/519 (4.05%)   Anaemia 1/519 (0.19%)   Blood bilirubin 0/519 (0.00%)   Leukopenia 0/519 (0.00%)   Neutropenia 1/519 (0.19%)   Arrhythmia 0/519 (0.00%)   Carotid artery thrombosis 1/519 (0.19%)   Ear infection 0/519 (0.00%)   Conjunctivitis 0/519 (0.00%)   Abdominal pain 1/519 (0.19%)   Anal fissure 0/519 (0.00%)   Constipation 0/519 (0.00%)   Diarrhoea 1/519 (0.19%) Adverse Events 2:   Total: 119/532 (22.37%)   Anaemia 1/532 (0.19%)   Blood bilirubin 1/532 (0.19%)   Leukopenia 1/532 (0.19%)   Neutropenia 5/532 (0.94%)   Arrhythmia 1/532 (0.19%)   Carotid artery thrombosis 0/532 (0.00%)   Ear infection 1/532 (0.19%)   Conjunctivitis 1/532 (0.19%)   Abdominal pain 1/532 (0.19%)   Anal fissure 1/532 (0.19%)   Constipation 1/532 (0.19%)   Diarrhoea 6/532 (1.13%)